Related Experiment Video

Updated: May 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its

Khaled H Barakat1, J Torin Huzil, Kirk E Jordan

  • 1Li Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, ‡Department of Oncology, and §Department of Physics, University of Alberta , Edmonton, Alberta P6G 2M7, Canada.

Molecular Pharmaceutics
|October 8, 2013
PubMed

Insights

Novel computational methods identified new Aurora kinase-A (AK-A) ligands. These ligands target cancer-driving mutations, overcoming drug resistance and improving inhibitor selectivity for better cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Aurora kinase-A (AK-A) is crucial for cell division and often overexpressed in cancers.
  • Existing AK-A inhibitors face challenges with drug resistance and cross-reactivity.
  • Understanding AK-A's interaction with inhibitors is vital for developing effective cancer drugs.

Purpose of the Study:

  • To discover novel AK-A ligands using virtual screening.
  • To identify ligands that bind to both wild-type AK-A and the T217D resistant mutation.
  • To find ligands with improved selectivity for the mutant AK-A variant.

Main Methods:

  • State-of-the-art virtual screening techniques were employed.
  • Computational screening identified potential AK-A ligands.
  • Ligand binding and selectivity were computationally assessed against wild-type and mutant AK-A.

Main Results:

  • A novel set of AK-A ligands was discovered through virtual screening.
  • Predicted ligands show strong binding to both wild-type and T217D mutant AK-A.
  • A subset of ligands demonstrated enhanced selectivity for the T217D mutant over wild-type AK-A.

Conclusions:

  • The identified ligands serve as valuable tools for drug development.
  • These ligands can help overcome AK-A T217D mutation-associated drug resistance.
  • The findings facilitate the design of new cancer treatment regimens with improved specificity and efficacy.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).